Improved metabolic control decreases platelet activation markers in patients with type-2 diabetes

被引:73
|
作者
Eibl, N
Krugluger, W
Streit, G
Schrattbauer, K
Hopmeier, P
Schernthaner, G
机构
[1] Rudolfstiftung Hosp, Dept Med, A-1030 Vienna, Austria
[2] Rudolfstiftung Hosp, Cent Lab, A-1030 Vienna, Austria
关键词
CD31; CD62P; CD63; metabolic control; platelet activation; type-2; diabetes;
D O I
10.1111/j.1365-2362.2004.01320.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Cardiovascular disease is associated with platelet dysfunction in patients with diabetes. Hyperglycaemia is known as an independent risk factor for micro- and macrovascular complications, and improvement of metabolic control has shown beneficial effects on diabetic late complications. Our study attempts to clarify the effect of improved metabolic control on platelet activation markers in patients with type-2 diabetes. Materials and methods Thirty patients were studied at baseline and 3 months after improvement of metabolic control and compared with an age-matched nondiabetic control group. Platelet activation markers (CD31, CD36, CD49b, CD62P and CD63) were assessed by flow cytometry analysis. Results Significantly more activated platelets were detected in patients with diabetes compared with controls. After 3 months' improvement of metabolic control, a significant decline of all platelet activation markers except CD36 was noted. Furthermore a significant correlation between CD62P, CD63 and HbA(1c) levels was observed. Conclusions We conclude therefore that improvement of metabolic control has a beneficial effect on platelet activation. This may have an implication in the pathogenesis of vascular disease in patients with type-2 diabetes.
引用
收藏
页码:205 / 209
页数:5
相关论文
共 50 条
  • [31] Oxidant/antioxidant status in Type-2 diabetes mellitus patients with metabolic syndrome
    Najafi, Ali
    Pourfarzam, Morteza
    Zadhoush, Fouzieh
    JOURNAL OF RESEARCH IN MEDICAL SCIENCES, 2021, 26 (01):
  • [32] Treatment for Patients with Type-2 Diabetes
    Landgraf, Ruediger
    Kellerer, Monika
    Aberle, Jens
    Fach, Eva-Maria
    Gallwitz, Baptist
    Hamann, Andreas
    Joost, Hans-Georg
    Klein, Harald
    Mueller-Wieland, Dirk
    Nauck, Michael A.
    Reuter, Hans-Martin
    Schreiber, Stephan
    Siegel, Erhard
    DIABETOLOGE, 2019, 15 (02): : 146 - 167
  • [33] Therapy for Patients with Type-2 Diabetes
    Landgraf, Ruediger
    Aberle, Jens
    Birkenfeld, Andreas L.
    Gallwitz, Baptist
    Kellerer, Monika
    Klein, Harald
    Mueller-Wieland, Dirk
    Nauck, Michael A.
    Reuter, Hans-Martin
    Siegel, Erhard
    DIABETOLOGIE UND STOFFWECHSEL, 2019, 14 : S167 - S187
  • [34] Treatment for Patients with Type-2 Diabetes
    Landgraf, Rueediger
    Aberle, Jens
    Birkenfeld, Andreas L.
    Gallwitz, Baptist
    Kellerer, Monika
    Klein, Harald H.
    Mueller-Wieland, Dirk
    Nauck, Michael A.
    Wiesner, Tobias
    Siegel, Erhard
    DIABETOLOGIE UND STOFFWECHSEL, 2021, 16 : S168 - S206
  • [35] Lipophilic index of serum phospholipids in patients with type 2 diabetes and atherosclerotic cardiovascular disease: links with metabolic control, vascular inflammation and platelet activation
    Rostoff, Pawel
    Drwila-Stec, Dominika
    Majda, Anna
    Stepien, Konrad
    Nessler, Jadwiga
    Gajos, Grzegorz
    CARDIOVASCULAR DIABETOLOGY, 2024, 23 (01)
  • [36] Metabolic flux in macrophages in obesity and type-2 diabetes
    Wong, Angela
    Sun, Qiuyu
    Latif, Ismail Ibrahim
    Karwi, Qutuba G.
    JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 2024, 27
  • [37] Metabolic syndrome in subjects with type-2 diabetes mellitus
    Alebiosu, CO
    Odusan, BA
    JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION, 2004, 96 (06) : 817 - 821
  • [38] Platelet activation in type 2 diabetes mellitus
    Ferroni, P
    Basili, S
    Falco, A
    Davì, G
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2004, 2 (08) : 1282 - 1291
  • [39] Impact of Metabolic Surgery on Type-2 Diabetes Remission
    Baiocchi, Cejana de Abrantes Figueiredo
    de Sa, Diana Aristotelis Rocha
    CURRENT DIABETES REVIEWS, 2021, 17 (07)
  • [40] A RANDOMISED CONTROL TRIAL OF COMPARITIVE EFFICACY OF METFORMIN, PIOGLITAZONE & ROSUVASTATIN IN PATIENTS WITH METABOLIC SYNDROME WITH TYPE-2 DIABETES
    Mukherjee, I.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2020, 22 : A241 - A242